Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers (ABC06)

• ClinicalTrials.gov Identifier: NCT01926236
• Recruitment Status: Completed
• First Posted: August 20, 2013
• Last Update Posted: January 28, 2020
• Sponsor: The Christie NHS Foundation Trust
• Collaborator: Cancer Research UK
• Information provided by (Responsible Party): Juan Valle, The Christie NHS Foundation Trust

Tracking Information

• First Submitted Date: August 17, 2013
• First Posted Date: August 20, 2013
• Last Update Posted Date: January 28, 2020
• Study Start Date: February 2014
• Actual Primary Completion Date: January 5, 2018 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: August 19, 2013): Overall survival [ Time Frame: Evaluated by monthly follow-up until 12 months after last patient included ]
• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: July 22, 2014)

• Progression-free survival [ Time Frame: Evaluated by monthly follow-up until 12 months after last patient included ]
  Clinical progression assessed monthly, radiological progression assessed to RECIST criteria every 12 weeks for patients in the chemotherapy arm.
• Response rate (chemotherapy arm only) [ Time Frame: After 12 weeks of treatment ]
• Toxicity (frequency of adverse events and serious adverse events) [ Time Frame: Evaluated monthly until 12 months after last patient included ]
  Events will be classified according to CTCAE V4.03
• Quality of life [ Time Frame: Evaluated every 3 months until 12 months after last patient included ]
  Assessed from patient completed questionnaire data: QLQ-C30 and QoL BiL
• Costs of health and social care [ Time Frame: Evaluated every 3 months until 12 months after last patient included ]
• Health status (Euroqol) [ Time Frame: Evaluated every 3 months until 12 months after last patient included ]
• Quality adjusted life years (QALYs) [ Time Frame: Evaluated every 3 months until 12 months after last patient included ]
  Estimated from Euroqol and survival using published utility tariffs

Original Secondary Outcome Measures (submitted: August 19, 2013)

• Progression-free survival [ Time Frame: Evaluated by monthly follow-up until 12 months after last patient included ]
  Clinical progression assessed monthly, radiological progression assessed to RECIST criteria every 12 weeks for patients in the chemotherapy arm.
• Response rate (chemotherapy arm only) [ Time Frame: After 12 weeks of treatment ]
• Toxicity (frequency of adverse events and serious adverse events) [ Time Frame: Evaluated monthly until 12 months after last patient included ]
  Events will be classified according to CTCAE V4.03
• Quality of life [ Time Frame: Evaluated every 3 months until 12 months after last patient included ]
  Assessed from patient completed questionnaire data: QLQ-C30 and QoL BiL
• Costs of health and social care [ Time Frame: Evaluated every 3 months until 12 months after last patient included ]
• Health status (Eurqol) [ Time Frame: Evaluated every 3 months until 12 months after last patient included ]
• Quality adjusted life years (QALYs) [ Time Frame: Evaluated every 3 months until 12 months after last patient included ]
  Estimated from Eurqol and survival using published utility tariffs

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers
• Official Title: A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy.
• Brief Summary: The purpose of this study is to determine whether fit patients (with ECOG performance score of 0-1) with advanced biliary tract cancer (ABC) benefit from chemotherapy in the second-line setting (after prior therapy with cisplatin and gemcitabine) in terms of overall survival.

Detailed Description

Active chemotherapy drugs for the treatment of ABC include gemcitabine, fluoropyrimidines and platinum agents. The randomized NCRN phase III ABC-02 trial provided level A evidence supporting first-line combination cisplatin and gemcitabine (CisGem) chemotherapy in ABC. To date, there is no randomized data to support the use of second-line chemotherapy in ABC. In this setting only a small number of retrospective and prospective (phase II) studies employing multiple different chemotherapy schedules have been conducted (level C). Thus, active symptom control (ASC) is the current standard of care after development of resistance to first-line chemotherapy. Oxaliplatin has activity in several gastrointestinal tumours and has synergistic activity with a favourable toxicity profile when used in combination with 5-FU. Several studies using mFOLFOX for biliary tract tumours have provided promising efficacy data and acceptable toxicity.

The aim of this trial is to determine if patients with ABC benefit with respect to survival from the addition of mFOLFOX chemotherapy to ASC in the second-line setting after progression to first-line treatment with CisGem. This study will establish the standard of care for patients with ABC who have progressed on first line CisGem chemotherapy.

This is a randomised phase III, multi-centre, controlled, open-label trial of patients with advanced biliary tract cancer with evidence of disease progression after prior CisGem chemotherapy treatment. Eligible patients (ECOG 0-1, adequate haematological, renal and liver function, adequate biliary drainage, with no evidence of ongoing infection) will be randomized to receive either ASC ("standard" arm) or ASC with oxaliplatin/5-FU chemotherapy ("experimental" arm). The total number of participants planned is 162 (randomized 1:1). At randomisation the following factors will be controlled for: serum albumin level, platinum sensitivity (determined from first-line therapy) and locally advanced vs metastatic disease.

The primary end point is overall survival. Quality of life and economic evaluation will assess the impact on patients and relative cost effectiveness of the intervention. Archival paraffin-embedded tissue will be collected at baseline and prospective blood samples (whole blood, serum and plasma) will be collected for translational research.

• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Biliary Tract Cancer
• Gallbladder Cancer
• Cholangiocarcinoma
• Ampullary Cancer

Intervention

• Other: Active Symptom Control
  Active Symptom Control: monthly clinical review and active symptom control as needed, including biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy, blood transfusion.
• Drug: L-folinic acid
  L-folinic acid 175mg (or folinic acid 350mg) q14d, up to 12 cycles
  Other Name: Folinic acid
• Drug: 5 FU
  5 FU 400 mg/m2 (bolus), 2400 mg/m2 (infusion), q 14d, up to 12 cycles
  Other Name: Fluorouracil
• Drug: Oxaliplatin
  Oxaliplatin 85mg/m2, q 14d, up to 12 cycles
  Other Name: Eloxatin

Study Arms

• Active Comparator: Arm A: Active symptom control (ASC)
  Active Symptom Control
  Intervention: Other: Active Symptom Control
• Experimental: Arm B: ASC with OxMdG chemotherapy
  Active Symptom Control with OxMdG chemo (Oxaliplatin, L-folinic acid & 5FU)
  Interventions:

  • Other: Active Symptom Control
  • Drug: L-folinic acid
  • Drug: 5 FU
  • Drug: Oxaliplatin

• Publications *: Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, Anthoney A, Maraveyas A, Iveson T, Waters JS, Hobbs C, Barber S, Ryder WD, Ramage J, Davies LM, Bridgewater JA, Valle JW; Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021 May;22(5):690-701. doi: 10.1016/S1470-2045(21)00027-9. Epub 2021 Mar 30.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: August 19, 2013): 162
• Original Estimated Enrollment: Same as current
• Actual Study Completion Date: January 2019
• Actual Primary Completion Date: January 5, 2018 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Histologically / cytologically verified, non-resectable or recurrent / metastatic cholangiocarcinoma, gallbladder or ampullary carcinoma.
• Patients must have failed no more than one prior course of chemotherapy (gemcitabine and cisplatin) with clear evidence of disease progression.
• ECOG performance status 0-1.
• Age >=18 years and life expectancy >3 months.
• Adequate renal function with serum urea and serum creatinine < 1.5 times upper limit of normal (ULN) and creatinine clearance >= 30ml/min
• Adequate haematological function: Hb >= 100g/l, WBC >= 3.0 x 10*9/L, ANC >= 2 x 10*9/L, platelet count >= 100 x 10*9/L
• Adequate liver function: total bilirubin < 60 μmol/L and ALP, along with AST and/or ALT ≤ 5 x ULN
• Adequate biliary drainage, with no evidence of ongoing infection (patients on maintenance antibiotics are eligible when acute sepsis has resolved).
• Women of child bearing age must have a negative pregnancy test prior to study entry and be using an adequate contraception method, which must be continued for 4 months after the study, unless child bearing potential has been terminated by surgery/radical radiotherapy
• Men must be willing to use an adequate method of contraception during chemotherapy and until 6 months after chemotherapy
• Patients must have given written informed consent
• Patients must be randomised and those allocated chemotherapy must start treatment within 6 weeks of diagnosis of disease progression

Exclusion criteria:

• Incomplete recovery from previous therapy or unresolved biliary tree obstruction (includes ongoing neuropathy of grade >1 from cisplatin)
• Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator, makes it undesirable for the patient to participate in the trial
• Evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator makes it undesirable for the patient to participate in the trial
• Any patient with a medical or psychiatric condition that impairs their ability to give informed consent
• Any other serious uncontrolled medical conditions
• Clinical evidence of metastatic disease to brain
• Any pregnant or lactating woman

• Clinically significant cardiovascular disease. [i.e. active; or <12 months since e.g. cerebrovascular accident, myocardial infarction, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, uncontrolled hypertension].

  **Hypertension grading of ≥ 3 is an exclusion criteria (CTCAE v4.03). However, patients who have controlled hypertension with medication and/or diet may be included at the investigator's discretion. (This should be noted in the medical history section of the CRF).

• Patients must not have a history of other malignant diseases within the last 5 years (other than adequately treated non-melanotic skin cancer or in-situ carcinoma of the uterine cervix).

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United Kingdom

Administrative Information

• NCT Number: NCT01926236
• Other Study ID Numbers: CFTSp048; A16281 ( Other Grant/Funding Number: Cancer Research UK (CTAAC) ); 2013-001812-30 ( EudraCT Number )
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Juan Valle, The Christie NHS Foundation Trust
• Original Responsible Party: Juan Valle, The Christie NHS Foundation Trust, Professor of Medical Oncology
• Current Study Sponsor: The Christie NHS Foundation Trust
• Original Study Sponsor: Same as current
• Collaborators: Cancer Research UK

Investigators

• Principal Investigator: Juan Valle, Prof; The Christie NHS Foundation Trust

• PRS Account: The Christie NHS Foundation Trust
• Verification Date: January 2020